These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32218661)

  • 1. Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020.
    Elkrief A; Joubert P; Florescu M; Tehfe M; Blais N; Routy B
    Curr Oncol; 2020 Feb; 27(1):52-60. PubMed ID: 32218661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
    Pabani A; Butts CA
    Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic agents for advanced non-small cell lung cancer.
    Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
    J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer.
    Fitzgerald K; Simone CB
    Thorac Surg Clin; 2020 May; 30(2):221-239. PubMed ID: 32327181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons.
    Rhodin KE; Rucker AJ; Ready NE; D'Amico TA; Antonia SJ
    J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1616-1623. PubMed ID: 31836182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
    Cetin B; Bilgetekin İ; Ozet A
    Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.
    Giustini NP; Jeong AR; Buturla J; Bazhenova L
    Clin Chest Med; 2020 Jun; 41(2):223-235. PubMed ID: 32402358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
    Broderick SR
    Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).
    Vergnenègre A; Chouaïd C
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):519-528. PubMed ID: 29869900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).
    McCarthy F; Roshani R; Steele J; Hagemann T
    J Leukoc Biol; 2013 Dec; 94(6):1201-6. PubMed ID: 23695306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.
    Daaboul N; Nicholas G; Laurie SA
    Curr Oncol; 2018 Jun; 25(Suppl 1):S77-S85. PubMed ID: 29910650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.
    Formisano L; Jansen VM; Marciano R; Bianco R
    Anticancer Agents Med Chem; 2018; 18(9):1235-1240. PubMed ID: 28901258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
    Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman J; Chirieac LR; D'Amico TA; DeCamp MM; Dilling TJ; Dobelbower M; Doebele RC; Govindan R; Gubens MA; Hennon M; Horn L; Komaki R; Lackner RP; Lanuti M; Leal TA; Leisch LJ; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
    J Natl Compr Canc Netw; 2017 Apr; 15(4):504-535. PubMed ID: 28404761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy and lung cancer: current developments and novel targeted therapies.
    Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
    Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options after first-line immunotherapy in metastatic NSCLC.
    Santos ES
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):221-228. PubMed ID: 32141356
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment patterns in non-small-cell lung cancer in China: Results from the CancerMPact survey 2020.
    Durbin L; Murali B; Li S; Zhao L; Hawthorne S; Kanas G; Davis C; Clark O
    Cancer Treat Res Commun; 2021; 29():100462. PubMed ID: 34583209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.
    Hallqvist A; Rohlin A; Raghavan S
    Scand J Immunol; 2020 Dec; 92(6):e12980. PubMed ID: 33015859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.